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ABSTRACT
The 6-min walk test (6MWT) has been used to exam-
ine subjective dyspnea, predict mortality and measure 
clinical outcomes in studies of patients with chronic 
pulmonary or heart disease. Although the 6MWT is 
useful in assessing the general ability for patients to 
perform daily physical activities, it is difficult to evalu-
ate time-dependent responses. To improve the 6MWT, 
we devised a new index–the number of steps walked per 
second (NSPS). Eleven healthy subjects and 7 patients 
with chronic obstructive pulmonary disease (COPD) 
performed the 6MWT. Then, we calculated the NSPS. 
The mean NSPS was significantly higher in the healthy 
subjects than in the COPD patients, while the coefficient 
of variation of the NSPS was significantly smaller in 
healthy subjects compared with COPD patients. Calcula-
tion of the NSPS was useful in evaluating walking pat-
terns. This modified 6MWT may be helpful for assessing 
the efficacy of rehabilitation and drug therapy for COPD. 
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The 6-min walk test (6MWT) has been used to assess 
functional status and measure clinical outcomes in stud-
ies of patients with chronic respiratory disease. This test 
assesses the farthest distance that a patient can walk in 
6 min.1 It was recently reported that the 6-min walk-
ing distance (6MWD) is useful for predicting mortality 
in patients with chronic obstructive pulmonary disease 
(COPD) but the efficacy of exercise-related oxygen 
desaturation is less clear.2 However, patients with se-
vere COPD frequently cannot walk for 6 min without 
stopping and may have to rest several times during the 
6MWT due to dyspnea. Moreover, some patients cannot 
walk at a constant pace, and the conventional 6MWT is 
Corresponding author: Naoto Burioka, MD, PhD
burioka@med.tottori-u.ac.jp
Received 2013 October 28
Accepted 2013 November 12 
Abbreviations: 6MWD, 6-min walking distance; 6MWT, 6-min 
walk test; COPD, chronic obstructive pulmonary disease; CV, co-
efficient of variation; NSPS, number of steps walked per second
difficult to evaluate in terms of time-dependent param-
eters such as the instantaneous walking speed. Since 
oxygen desaturation can improve after resting, the rest-
ing time and walking pattern may influence the results 
of this test in COPD patients. We developed a modified 
6MWT in which the walking pattern was examined by 
determining the number of steps per second (NSPS).
 
SUBJECTS AND METHODS 
Subjects and patients
Subjects and patients: Eleven healthy subjects (6 males 
and 5 females) and 7 clinically stable male patients with 
COPD participated in this study (Table 1). Exclusion 
criteria were unstable cardiovascular, orthopedic or neu-
rologic conditions. This study was approved by Tottori 
University and the Hitachi Memorial Hospital ethical 




The test was conducted in flat corridors with lengths of 
54 or 74 m at Tottori University or Hitachi Memorial 
Hospital, respectively, according to the published guide-
line.1 Oxygen saturation of arterial blood was measured 
by pulse oximetry (SpO2) with a finger sensor (Pulsox 
300i, Konica-Minolta, Tokyo, Japan) and was continu-
ously recorded during the test. Then pulse oximetry 
variables were analyzed by DS-5 Pulsox analysis soft-
ware (Konica-Minolta). The severity of dyspnea was 
subjectively assessed before and after the 6MWT using 
a modified Borg scale.3 It has been reported that at least 
2 practice walks should be performed before the 6MWT 
because training influences the results.4, 5 Healthy sub-
jects did 2 practice walks before the 6MWT, which was 
performed at the 3rd trial. COPD patients performed at 
least 2 practice walks on another day before the actual 
test because dyspnea and fatigue could influence the 
results of the 6MWT if patients practiced on the same 
day. The patients were allowed to sit on a chair to rest if 
needed, and resumed walking when they had recovered 
sufficiently. The duration of every rest was measured 
with a stopwatch. All of the walking tests were recorded 
by digital video and the 6MWD was measured.
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  Healthy Patients with
 subjects  COPD Pvalue*
 Number of subjects  11  7 
Age (yr)  68.6 (5.4)  70.7 (4.8) 0.316
Height (m)   1.58 (0.07)   1.60 (0.06) 0.934
Weight (kg)  61.0 (8.3)  48.7 (7.9) 0.012
FVC (L)   2.98 (0.72)   2.78 (0.92) 0.696
FEV1 (L)   2.48 (0.62)   1.34 (0.75) 0.008
FEV1, % predicted (%) 103.2 (14.2)  55.2 (27.1) 0.0018
6MWD (m) 486.9 (35.0) 289.5 (123.7) 0.005
Total number of steps 711.9 (47.1) 511.0 (153.5) 0.009
Mean NSPS (step/s)   1.98 (0.13)   1.42 (0.43) 0.0009
CV of NSPS (%)   7.4 (1.3) 44.7 (45.3) 0.0097
Total resting time (s)   0   65.6 (83.8) 0.0062
Delta Borg scale   0.1 (0.2)   1.6 (1.1) 0.002
Lowest SpO2 (%)  94.4 (1.2)  88.0 (5.7) 0.0052
Mean SpO2 (%)  95.5 (0.9)  90.9 (4.1) 0.0043 
Fig. 1. Walking patterns of a healthy subject and COPD 
patients based on the NSPS. The healthy subject (A: a 
66-year-old woman) and the COPD patient with rest (B: 
Calculating the NSPS
The number of steps walked by each subject every 
5 s was counted manually with a hand counter 
while viewing a video monitor. The walking speed 
(m/s) can be considered as the average step length 
(m/step) × NSPS (step/s). We defined that NSPS 
was calculated as the number of steps walked in 
a 5-s period divided by 5, and this was consecu-
tively done 72 times (360 s ÷ 5 s) in each subject. 
Because NSPS is proportional to the walking 
speed, it usually decreases when a patient walks 
more slowly and falls to zero if the patient stops 
walking. The mean value of NSPS was defined as 
[  NSPS(5k)] ÷ 72, where NSPS(5k) is the value 
of NSPS at 5k s (k = 1, 2, 3, . . . , 72). The coeffi-
cient of variation (CV) of NSPS was calculated as 
Table 1. Profile of the subjects and results of the 
6MWT: average NSPS
 Values, mean (SD). 
* Mann-Whitney’s U test. 
 6MWD, 6-min walking distance; 6MWT, 6-min walk test; 
COPD, chronic obstructive pulmonary disease; CV, coefficient 
of variation; FVC, Forced vital capacity, FEV1, Forced expira-
tory volume in 1 s; NSPS, number of steps walked per second.
 The NSPS was calculated as [steps walked in 5 s]  0.2, and was 
calculated 72 times (360 s ÷ 5 s) in each subject.
 The CV of NSPS was calculated as [SD/mean NSPS]  100 (%).
 Delta Borg scale: modified Borg scale after walking – modified 
Borg scale before walking.
follows: [SD/mean of NSPS] × 100 (%). The mean and 
CV of NSPS were determined in each subject. 
  
Statistical analyses
The values are presented as the mean (SD). We used 
Mann-Whitney’s U test for the assessment of any dif-
ference between healthy subjects and COPD patients 
(StatFlex, ViewFlex, Tokyo, Japan). Differences were 
considered to be statistically significant at P < 0.05.
RESULTS 
Figure 1 shows examples of the walking pattern deter-
mined from the NSPS in a healthy subject and 2 COPD 
patients with and without rest. NSPS increased as the 
walking pace became faster. While the healthy subject 
walked without resting, the patients rested for a total of 
83 s (Fig. 1B). Table 1 shows the characteristics of all 
subjects and the results of the 6MWT with NSPS. The 
6MWD of the healthy subject [486.9 (35.0) m] was sig-
nificantly longer than that of the patients [289.5 (123.7) 
m]. Four of the 7 patients had to rest on a chair [1.0 (1.2) 
times] during the 6MWT, and the total resting time was 
65.6 (83.8) s. In contrast, the healthy subject did not stop 
during the test. The mean NSPS of the healthy subject 
[1.98 (0.13) step/s] was significantly larger than that of 
a 64-year-old man) and the COPD patient without rest (C: a 68-year-old man) walked 504.5 m, 224.5 m and 356.5 m, respectively. Al-
though the healthy could walk without stopping, the patient (B) rested for 83 s. When the walking pace is slower, the NSPS is smaller, and 
becomes zero if the patient stops walking. COPD, chronic obstructive pulmonary disease; NSPS, number of steps per second.
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the patients [1.42 (0.43) step/s]. The CV of NSPS, which 
assesses both the walking pace and the resting time, also 
showed a significant difference between the healthy sub-
jects [7.4 (1.3) %] and the COPD patients [44.7 (45.3) %] 
(Table1). The 6MWD of the patients without rest [405.0 
(42.9) m] was significantly longer than that with rest 
[202.9 (77.7) m] (P < 0.05). The mean NSPS of patients 
without rest [1.80 (0.10) step/s] was significantly larger 
than that with rest [1.20 (0.37) step/s] (P < 0.05). The CV 
of NSPS of patients without rest [8.0 (1.4) %] was sig-
nificantly smaller than that with rest [72.2 (41.9) %] (P < 
0.05). The lowest SpO2 of patients without rest [92.7 (2.1) 
%] was significantly higher than that with rest [84.5 (4.9) 
%] (P < 0.05).
DISCUSSION
To improve the 6MWT, we determined NSPS as a new 
index. When we performed this modified 6MWT in 
healthy subjects and COPD patients, we found that the 
NSPS was useful for examining the walking property in 
the 6MWT. 
 The 6MWT has been reported to predict mortality 
in COPD patients2, 6 and this test has been used in many 
studies. Golpe et al.2 recently reported that exercise-
related oxygen desaturation during the 6MWT was 
not an independent predictor according to multivariate 
analysis. However, some severe COPD patients cannot 
walk for 6 min without resting, and their walking pace is 
slower than that of healthy subjects. Some of our COPD 
patients rested during the 6MWT, and exercise-related 
oxygen desaturation could improve after resting. There-
fore, if exercise-related oxygen desaturation is used as 
an index for predicting mortality, the resting time needs 
to be considered and previous reports are not clear 
about this point. In the present preliminary study, we 
examined the NSPS as a new index for the 6MWT that 
could be calculated easily. The mean and CV of NSPS 
in COPD patients were significantly different with and 
without rest. In particular, the CV of NSPS is an index 
of both the walking pace and the resting time. A graph 
of NSPS versus time displays the walking pattern of a 
patient during the 6MWT, and the results can be easily 
interpreted. 
 Consideration of walking steps during 6MWT may 
contribute new analyses of physiological condition in pa-
tients with COPD. Moreover, it has been reported that a 
3-dimensional accelerometer can accurately detect steps 
while a subject is walking.7 Use of an accelerometer 
would allow the NSPS to be computed automatically. 
The present study has several limitations with the most 
obvious being its relatively small sample size. Also, we 
did not investigate a random sample of COPD patients 
with a spectrum of disease severity. We could not com-
pare the clinical efficacy between 6MWD and NSPS. 
Further studies are needed to clarify the clinical useful-
ness and estimate whether the prognosis and mortality 
in COPD patients can be predicted by our new indices 
for the 6MWT. 
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